After a sell-off, this medical device stock looks like a gift for patient investors
Overblown fears surrounding GLP-1 weight loss drugs were already pressuring the stock when an onboarding stumble triggered a sell-off.
TL;DR
- Insulet's stock is undervalued due to a temporary patient retention issue in the U.S. Type 2 diabetes market, not a demand problem.
- GLP-1 weight loss drugs are expected to increase the number of Type 2 diabetes patients requiring insulin, potentially expanding Insulet's market.
- The company's Omnipod insulin delivery system offers competitive advantages, including a tubeless design and accessibility through pharmacies.
- Insulet's valuation is at its lowest in a decade, presenting an opportunity for significant appreciation with a modest re-rating.
- International growth is accelerating, and the company has a strong balance sheet and expanding gross margins.